CAR-T Cell Therapy Market
Number of pages: 100 | Report Format: PDF | Published date: May 04, 2023
Historical Years – 2021 | Base Year – 2022 | Forecasted Years – 2023-2031
|
Report Attribute |
Details |
|
Market Size Value in 2022 |
US$ 2.46 billion |
|
Revenue Forecast in 2031 |
US$ 25.40 billion |
|
CAGR |
29.60% |
|
Base Year for Estimation |
2022 |
|
Forecast Period |
2023 to 2031 |
|
Historical Year |
2021 |
|
Segments Covered |
Drug type, Indication, and Region |
|
Regional Scope |
North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
According to the deep-dive market assessment study by Growth Plus Reports, the global CAR-T cell therapy market is expected to register a revenue CAGR of 29.60% to reach US$ 25.40 billion by 2031.
CAR-T Cell Therapy Market Fundamentals
CAR-T cell therapy (Chimeric Antigen Receptor T-cell therapy) is a type of immunotherapy that uses genetically modified T-cells to fight cancer. T-cells are a type of immune cell in the body that can recognize and destroy cancer cells. In CAR-T cell therapy, T-cells are collected from a patient's blood and modified in a laboratory to produce chimeric antigen receptors (CARs) on their surface. These CARs are designed to recognize and bind to specific proteins, or antigens, present on cancer cells' surfaces. Once the CAR-T cells are reinfused into the patient's bloodstream, they seek out and destroy cancer cells that express the targeted antigen. CAR-T cell therapy has shown promising results in treating certain types of blood cancers, such as acute lymphoblastic leukemia and non-Hodgkin lymphoma. It has been approved by regulatory agencies in the United States and Europe.
This report is an important tool for the industry stakeholders to gather all the information about the market, customers, and competition. The report also provides the readers with valuable insights on the segmentation, regions, market size & forecast, revenue CAGRs, and other valuable data to help make informed strategic decisions. The study compiles information gathered from industry participants and specialists across the industry value chain. The report also taps into the qualitative and quantitative assessments by industry analysts. Our reports use different methods for estimating the market size and forecast, including secondary research, surveys and interviews, and statistical modeling. With these steps, our reports provide the most accurate market data. These datasets will cumulatively provide in-depth CAR-T cell therapy market forecasts to the industry stakeholders.
[1254]
CAR-T Cell Therapy Market Dynamics
The growing incidence of cancer worldwide is a significant driver of the CAR-T cell therapy market. As cancer rates continue to rise, there is a growing need for more effective and targeted cancer treatments such as CAR-T cell therapy. The development of gene editing technologies such as CRISPR has made it possible to precisely modify T-cells to produce CARs that can recognize and target specific cancer cells. Additionally, the increasing use of automation and robotics in cell therapy manufacturing reduces the cost and increases CAR-T cell therapy's scalability. The approval of CAR-T cell therapies by regulatory agencies such as the US FDA and the European Medicines Agency (EMA) has given patients and healthcare providers greater access to this innovative treatment. As more CAR-T cell therapies are approved and adopted, the market is expected to grow significantly. There is a significant amount of research and development taking place in the field of CAR-T cell therapy, with many companies investing heavily in this area. This has resulted in the development new and innovative CAR-T cell therapies that are more effective, safer, and easier to manufacture. For instance, there are some pipeline CAR-T cell therapy drugs that are under clinical trials, such as JWCAR029, CT 103A, CEA CAR T, Descartes-11, CTL119, TT11, CD19-targeted CAR-T cells, and MB-CART2019. Moreover, the complexity of CAR-T cell therapy requires collaboration between academic institutions, pharmaceutical companies, and contract manufacturing organizations. This has led to increased partnerships and collaborations between these entities, developing new CAR-T cell therapies and expanding the market.
CAR-T cell therapy is a highly personalized and complex treatment, which makes it expensive. The high cost of CAR-T cell therapy can make it inaccessible to many patients, particularly in developing countries, and can also limit its adoption by healthcare providers. Although CAR-T cell therapy has shown promising results in treating certain types of cancer, it can also have severe side effects, including cytokine release syndrome (CRS) and neurotoxicity. These side effects can be life-threatening and require close monitoring and management. CAR-T cell therapy is only approved for treating certain types of blood cancers, including acute lymphoblastic leukemia and non-Hodgkin lymphoma. CAR-T cell therapies that can treat solid tumors, representing a significant proportion of cancer cases, need to be developed. The manufacturing of CAR-T cell therapy is complex and requires specialized facilities and equipment. These facilities' limited availability can limit CAR-T cell therapy's scalability and increase manufacturing costs. The regulatory approval process for CAR-T cell therapy can be lengthy and complex, thus delaying the availability of these treatments to patients. There is also a need to develop standardized regulatory guidelines to ensure the safety and efficacy of CAR-T cell therapies.
CAR-T Cell Therapy Market Ecosystem
CAR-T Cell Therapy Market, by Drug Type
CAR-T Cell Therapy Market, by Indication
CR-T Cell Therapy Market by Indication
[852]
The diffuse large B-cell lymphoma (DLBCL) segment accounts for a sizeable revenue share in the global market. Diffuse large B-cell lymphoma is a type of aggressive non-Hodgkin lymphoma that is the most common subtype of non-Hodgkin lymphoma. Diffuse large B-cell lymphoma is a rapidly growing market for CAR-T cell therapy because it is a disease with high unmet medical needs where other treatment options have been limited. Additionally, diffuse large B-cell lymphoma is an attractive target for CAR-T cell therapy because it expresses the CD19 antigen, a common target for CAR-T cell therapy. CD19-targeted CAR-T cell therapy has shown promising clinical results in diffuse large B-cell lymphoma patients, leading to regulatory approval of CD19-targeted CAR-T cell therapies for this indication. Moreover, the increasing prevalence of diffuse large B-cell lymphoma and the growing demand for personalized cancer treatments are expected to drive the growth of the diffuse large B-cell lymphoma segment in the CAR-T cell therapy market in the coming years.
Segmentation of the market refers to the division of the industry into subgroups based on factors such as drug type and indication. Market segmentation data helps businesses to understand the preferences and unique needs of different customer groups and develop targeted sales strategies. This information also helps in identifying potential CAR-T cell therapy market growth opportunities.
CAR-T Cell Therapy Market by Region
Asia Pacific registered as the fastest-growing region in the global market and is expected to account for notable revenue shares during the predicted timeframe. Asia Pacific region has a high burden of cancer, and the incidence of cancer is increasing at an alarming rate in the region. This has led to a growing demand for effective cancer treatments, including CAR-T cell therapy. The Asia Pacific region has a large population, and a significant proportion of this population is affected by cancer. This has resulted in a large potential market for CAR-T cell therapy in the region. Many countries in the Asia Pacific region are increasing their healthcare spending, developing better healthcare infrastructure, and adopting advanced medical technologies, including CAR-T cell therapy. Several countries in the Asia Pacific region have established regulatory frameworks for the approval of CAR-T cell therapy, thus, supporting the market growth in the region. Many companies in the Asia Pacific region are investing in research and development activities related to CAR-T cell therapy, leading to the development of new and innovative products.
Based on the regions, the global CAR-T cell therapy market is segmented into:
Regional demarcation of the industry will provide information on geographic pockets regarding the CAR-T cell therapy market outlook, size, share, and growth rate. This data helps businesses evaluate the expansion potential into new regional markets, understand the competitive threats across different regions, and develop localized sales and expansion strategies.
Key Components of the Report
CAR-T Cell Therapy Market Competitive Landscape
Novartis AG, Bristol-Myers Squibb Company, Amgen Inc., Gilead Sciences Inc. (Kite Pharma), Johnson & Johnson, Eli Lilly and Company, Sorrento Therapeutics Inc., ACROBiosystems, Celyad Oncology, Sangamo Therapeutics Inc., Servier Laboratories, Noile-Immune Biotech Inc., Miltenyi Biotec, and other notable players.
The market competitive landscape is performed by collecting and analyzing information about the key competitors, the present industry trends, and market dynamics. It includes information collection and analysis on factors such as products, pricing, geographic outreach, customer demographics, marketing strategies, and recent developments. Competitive landscape assessment will help businesses identify the current prevalent or potential opportunities and threats, keeping in mind the industry trends.
Key Strengths of Our Report
Target Audience to Benefit from this Report.
Reasons to Buy this Report
CAR-T cell therapy (Chimeric Antigen Receptor T-cell therapy) is a type of immunotherapy that uses genetically modified T-cells to fight cancer.
The market size of the CAR-T cell therapy market in 2022 will be US$ 2.46 billion.
North America accounts for the largest global CAR-T cell therapy market revenue share.
The global CAR-T cell therapy market is estimated to grow at a revenue CAGR of 29.60% from 2023 to 2031
The rising prevalence of cancer and advancement in therapy due to growing R&D activities are prominent trends in global CAR-T cell therapy.
Increasing research and development activities and rising awareness are a few opportunities in the global CAR-T cell therapy market.
The high cost of the therapy and safety concerns are the major restraining factor that can hamper the overall market growth.
Novartis AG, Bristol-Myers Squibb Company, Eli Lilly and Company, and other notable players are major global CAR-T cell therapy market players.
Diffuse large B-cell lymphoma segment accounts for the highest revenue share in the global market.
*Insights on financial performance are subject to the availability of information in the public domain